Leap Therapeutics (LPTX) Competitors $0.42 +0.01 (+1.73%) Closing price 04:00 PM EasternExtended Trading$0.42 +0.00 (+0.31%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LPTX vs. OTLK, OKYO, RPTX, BMEA, FBRX, CLSD, GANX, KLRS, DTIL, and VNRXShould you be buying Leap Therapeutics stock or one of its competitors? The main competitors of Leap Therapeutics include Outlook Therapeutics (OTLK), OKYO Pharma (OKYO), Repare Therapeutics (RPTX), Biomea Fusion (BMEA), Forte Biosciences (FBRX), Clearside Biomedical (CLSD), Gain Therapeutics (GANX), Allovir (KLRS), Precision BioSciences (DTIL), and VolitionRx (VNRX). These companies are all part of the "pharmaceutical products" industry. Leap Therapeutics vs. Outlook Therapeutics OKYO Pharma Repare Therapeutics Biomea Fusion Forte Biosciences Clearside Biomedical Gain Therapeutics Allovir Precision BioSciences VolitionRx Leap Therapeutics (NASDAQ:LPTX) and Outlook Therapeutics (NASDAQ:OTLK) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, community ranking, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations. Do insiders & institutionals believe in LPTX or OTLK? 30.5% of Leap Therapeutics shares are owned by institutional investors. Comparatively, 11.2% of Outlook Therapeutics shares are owned by institutional investors. 7.5% of Leap Therapeutics shares are owned by insiders. Comparatively, 4.8% of Outlook Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, LPTX or OTLK? Leap Therapeutics has a beta of -0.23, suggesting that its share price is 123% less volatile than the S&P 500. Comparatively, Outlook Therapeutics has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500. Does the MarketBeat Community prefer LPTX or OTLK? Leap Therapeutics received 127 more outperform votes than Outlook Therapeutics when rated by MarketBeat users. However, 70.76% of users gave Outlook Therapeutics an outperform vote while only 68.37% of users gave Leap Therapeutics an outperform vote. CompanyUnderperformOutperformLeap TherapeuticsOutperform Votes29468.37% Underperform Votes13631.63% Outlook TherapeuticsOutperform Votes16770.76% Underperform Votes6929.24% Do analysts prefer LPTX or OTLK? Leap Therapeutics currently has a consensus target price of $4.92, suggesting a potential upside of 1,097.43%. Outlook Therapeutics has a consensus target price of $9.60, suggesting a potential upside of 405.26%. Given Leap Therapeutics' higher possible upside, research analysts clearly believe Leap Therapeutics is more favorable than Outlook Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Leap Therapeutics 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25Outlook Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Is LPTX or OTLK more profitable? Outlook Therapeutics' return on equity of 0.00% beat Leap Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Leap TherapeuticsN/A -116.24% -93.18% Outlook Therapeutics N/A N/A -225.12% Does the media refer more to LPTX or OTLK? In the previous week, Outlook Therapeutics had 5 more articles in the media than Leap Therapeutics. MarketBeat recorded 6 mentions for Outlook Therapeutics and 1 mentions for Leap Therapeutics. Leap Therapeutics' average media sentiment score of 1.00 beat Outlook Therapeutics' score of 0.18 indicating that Leap Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Leap Therapeutics Positive Outlook Therapeutics Neutral Which has stronger valuation & earnings, LPTX or OTLK? Outlook Therapeutics is trading at a lower price-to-earnings ratio than Leap Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLeap TherapeuticsN/AN/A-$81.41M-$1.70-0.24Outlook TherapeuticsN/AN/A-$75.37M-$0.91-2.09 SummaryOutlook Therapeutics beats Leap Therapeutics on 8 of the 15 factors compared between the two stocks. Get Leap Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LPTX vs. The Competition Export to ExcelMetricLeap TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.02M$6.70B$5.51B$8.63BDividend YieldN/A2.50%5.27%4.19%P/E Ratio-0.218.6627.2120.15Price / SalesN/A255.59414.99161.57Price / CashN/A65.8538.2534.64Price / Book0.176.626.954.72Net Income-$81.41M$143.26M$3.23B$248.00M7 Day Performance10.82%9.23%5.21%3.71%1 Month Performance22.57%18.26%13.98%10.34%1 Year Performance-82.07%8.62%32.33%15.16% Leap Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LPTXLeap Therapeutics2.7239 of 5 stars$0.42+1.7%$4.92+1,077.1%-81.7%$17.31MN/A-0.2240Positive NewsOTLKOutlook Therapeutics1.8373 of 5 stars$1.77-3.8%$10.20+476.3%-72.0%$59.42MN/A-0.2420Gap UpHigh Trading VolumeOKYOOKYO Pharma2.1256 of 5 stars$1.75-5.4%$7.00+300.0%+65.4%$59.21MN/A0.007RPTXRepare Therapeutics2.3549 of 5 stars$1.37flat$4.50+228.5%-62.1%$58.76M$1.07M-0.69180Positive NewsBMEABiomea Fusion2.8212 of 5 stars$1.55+7.6%$22.60+1,358.1%-36.5%$58.24MN/A-0.3950Gap UpFBRXForte Biosciences2.9817 of 5 stars$8.83+3.9%$61.00+590.8%+51,134.8%$58.13MN/A-0.545Gap UpCLSDClearside Biomedical2.4045 of 5 stars$0.74-2.8%$4.80+548.7%-37.6%$57.50M$3.76M-1.6430GANXGain Therapeutics1.9327 of 5 stars$1.93+9.0%$8.20+324.9%-13.2%$57.05M$50,000.00-1.7520Positive NewsKLRSAllovirN/A$3.00+3.4%N/AN/A$56.11MN/A0.00110News CoverageAnalyst DowngradeDTILPrecision BioSciences4.0709 of 5 stars$5.04+4.3%$47.00+832.5%-56.6%$55.88M$51.14M84.01200News CoveragePositive NewsVNRXVolitionRx2.0811 of 5 stars$0.53+5.2%$3.75+608.9%-18.1%$54.50M$1.31M-1.4780Analyst ForecastHigh Trading Volume Related Companies and Tools Related Companies Outlook Therapeutics Alternatives OKYO Pharma Alternatives Repare Therapeutics Alternatives Biomea Fusion Alternatives Forte Biosciences Alternatives Clearside Biomedical Alternatives Gain Therapeutics Alternatives Allovir Alternatives Precision BioSciences Alternatives VolitionRx Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LPTX) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Urgent Crypto Market Alert The last time we saw this pattern, early investors made fortunes...Crypto 101 Media | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWhy 2026 will be a disaster for many Americans2025 Market Crash The first-quarter stock crash left investors wondering what lies ahead. Today 50-year Wal...Chaikin Analytics | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Leap Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Leap Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LPTX Stock Free LPTX Stock Alerts